KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Immunogenicity and safety of an egg culture-based quadrivalent inactivated non-adjuvanted subunit influenza vaccine in subjects ≥3 years: A randomized, multicenter, double-blind, active-controlled phase III, non-inferiority trial.

Yuhui Zhang, Yanxia Wang, Chunyu Jia, Guangfu Li, Wei Zhang, Qin Li, Xiaofen Chen, Wenna Leng, Lili Huang, Zhiqiang Xie, Huiping Zhang, Wangyang You, Rui An, Hongyan Jiang, Xue Zhao, Siyan Cheng, Jiebing Tan, Weiyang Cui, Feilong Gao, Weifeng Lu, Yuping Wang, Yongli Yang, Shengli Xia, Shuai Wang

Vaccine 40(34) 4933-4941

PMID35810063
PMCID-
DOI10.1016/j.vaccine.2022.06.078
发表日期2022-07-09
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

Subunit influenza vaccine only formulated with surface antigen proteins has better safety profiles relative to split-virion influenza vaccine. Compared to the traditional quadrivalent split-virion influenza vaccine, a novel quadrivalent subunit influenza vaccine is urgently needed in China. We completed a phase 3, randomized, double-blind, active-controlled, non-inferiority clinical study at two sites in Henan Province, China. Eligible volunteers were split into four age cohorts (3-8 years, 9-17 years, 18-64 years, and ≥ 65 years, based on their dates of birth) and randomly assigned (1:1) to the subunit and the split-virion ecNAIIV4 groups. All volunteers were intramuscularly administered a single vaccine dose at baseline, and children aged 3-8 years received a boosting dose at day 28. And the immune response was evaluated by measuring hemagglutinin-inhibition antibody titers against the four vaccine strains in blood samples. Safety profiles had nonsignificant differences between the study groups in ≥ 3 years cohort. Most adverse reactions post-vaccination, both local and systemic, were mild to moderate and resolved within 3 days. And no serious adverse events occurred. The immunogenicity of the trial vaccine was non-inferior to the comparator. Further, a two-dose vaccine series can provide better seroprotection than that of a one-dose series in children aged 3-8 years, with clinically acceptable safety profiles. Clinical Trials Registration. ChiCTR2100049934.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。